Back to Browse Journals » Nutrition and Dietary Supplements » Volume 6

Dermaval™ inhibits glucose-induced neutrophil elastase activity in healthy subjects

Authors Reyes-Izquierdo T, Nemzer B, Argumedo R, Shu C, Pietrzkowski Z

Received 31 August 2013

Accepted for publication 29 October 2013

Published 23 December 2013 Volume 2014:6 Pages 1—7


Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 3

Tania Reyes-Izquierdo,1 Boris Nemzer,2 Ruby Argumedo,1 Cynthia Shu,1 Zb Pietrzkowski1

1Applied BioClinical Inc., Irvine, CA, 2FutureCeuticals Inc, Momence, IL, USA

Background: Dermaval™ is a composite formulation of various phytochemical-rich plant materials as quantified using high-performance liquid chromatography. This blend exerts inhibitory activity on human neutrophil elastase (HNE). An acute, crossover clinical study was performed to assess the effects of Dermaval on glucose-induced HNE activity in 20 healthy subjects.
Methods: Participants served as their own controls during this 3-day trial. On day 1, all study participants were fasted and given only 300 mL of water. Blood was drawn before treatment and 60 and 120 minutes post treatment. On day 2, participants were fasted, treated with 75 g of glucose, and similarly tested. On day 3, participants consumed a 50 mg serving of Dermaval followed by 75 g of glucose 15 minutes later. HNE concentration and HNE total activity were determined using enzyme-linked immunosorbent assay.
Results: Average values for HNE activity in the control group (day 1) did not change. Treatment with a single dose of glucose (day 2) increased blood HNE activity by 175% over baseline levels (P=0.005) during the first 60 minutes. Pretreatment with Dermaval on day 3 prevented the glucose-induced increase in HNE activity (P=0.005 at 60 minutes and P=0.03 at 120 minutes versus respective day 2 values). Interestingly, ingestion of 75 g of glucose resulted in the same blood glucose levels on days 2 and 3, indicating that ingestion of Dermaval did not affect glucose absorption.
Conclusion: These results suggest that Dermaval acutely inhibits glucose-induced HNE activity. Further investigations are needed to elucidate the direct and/or indirect mechanism of this effect and to verify whether treatment with Dermaval without glucose may acutely affect activity of HNE as well.

Keywords: crossover study, human neutrophil elastase, glucose

Download Article [PDF] View Full Text [HTML] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at:

Other articles by this author:

Short-term efficacy of calcium fructoborate on subjects with knee discomfort: a comparative, double-blind, placebo-controlled clinical study

Pietrzkowski Z, Phelan MJ, Keller R, Shu C, Argumedo R, Reyes-Izquierdo T

Clinical Interventions in Aging 2014, 9:895-899

Published Date: 5 June 2014

Betalain-rich red beet concentrate improves reduced knee discomfort and joint function: a double blind, placebo-controlled pilot clinical study

Pietrzkowski Z, Argumedo R, Shu C, Nemzer B, Wybraniec S, Reyes-Izquierdo T

Nutrition and Dietary Supplements 2014, 6:9-13

Published Date: 10 March 2014

Readers of this article also read:

The influence of age on health valuations: the older olds prefer functional independence while the younger olds prefer less morbidity

Hofman CS, Makai P, Boter H, Buurman BM, de Craen AJ, Olde Rikkert MGM, Donders R, Melis RJF

Clinical Interventions in Aging 2015, 10:1131-1139

Published Date: 8 July 2015

Issues in assessing products for the treatment of hemophilia – the intersection between efficacy, economics, and ethics

Farrugia A, Noone D, Schlenkrich U, Schlenkrich S, O’Mahony B, Cassar J

Journal of Blood Medicine 2015, 6:185-195

Published Date: 15 June 2015

A new recombinant factor VIII: from genetics to clinical use

Santagostino E

Drug Design, Development and Therapy 2014, 8:2507-2515

Published Date: 12 December 2014

Association of BDNF Val66Met polymorphism with HPA and SAM axis reactivity to psychological and physical stress

Tsuru J, Tanaka Y, Ishitobi Y, Maruyama Y, Inoue A, Kawano A, Ikeda R, Ando T, Oshita H, Aizawa S, Masuda K, Higuma H, Kanehisa M, Ninomiya T, Akiyoshi J

Neuropsychiatric Disease and Treatment 2014, 10:2123-2133

Published Date: 11 November 2014

Caregiver burden and coping strategies in caregivers of patients with Alzheimer’s disease

Iavarone A, Ziello AR, Pastore F, Fasanaro AM, Poderico C

Neuropsychiatric Disease and Treatment 2014, 10:1407-1413

Published Date: 29 July 2014

Dissociative symptoms reflect levels of tumor necrosis factor alpha in patients with unipolar depression

Bizik G, Bob P, Raboch J, Pavlat J, Uhrova J, Benakova H, Zima T

Neuropsychiatric Disease and Treatment 2014, 10:675-679

Published Date: 25 April 2014

Treatment and management of myelofibrosis in the era of JAK inhibitors [Corrigendum]

Keohane C, Radia DH, Harrison CN

Biologics: Targets and Therapy 2013, 7:231-232

Published Date: 31 October 2013

Corrigendum: Softec HD hydrophilic acrylic intraocular lens: biocompatibility and precision

Espandar L, Sikder S, Moshirfar M

Clinical Ophthalmology 2011, 5:159-160

Published Date: 6 February 2011